Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)

Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.

Podrobná bibliografia

Vydané v:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Ročník 16; číslo 4; s. S30 - S31
Hlavní autori:	Ozaka, Masato, Ishii, Hiroshi, Sato, Tosiya, Ueno, Makoto, Ikeda, Masafumi, Uesugi, Kazuhiro, Sata, Naohiro, Miyashita, Kouichirou, Mizuno, Nobumasa, Tsuji, Kunihiro, Okusaka, Takuji, Furuse, Junji
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Philadelphia Elsevier B.V 01.08.2016 Elsevier Limited
Predmet:	Chemotherapy Confidence intervals Endocrinology & Metabolism Gastroenterology and Hepatology Metastasis Neutropenia Pancreatic cancer
ISSN:	1424-3903, 1424-3911
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!